Fetching the screen from the local API.
The daily brief
Health and medicine from the desks that moved today. Refreshed every morning; every headline opens at its publisher.
Physician groups are seeking a delay for a new Medicare demonstration model. The model debuts January 1 and requires doctors treating low back pain and congestive heart failure to meet performance standards or face payment penalties. That means those physicians could see payment consequences tied to the standards if the model starts on schedule.
Hims & Hers struck a deal with Eli Lilly to offer the drugmaker’s branded obesity treatments through its online health and wellness platform.
Doximity is expanding its clinical AI footprint to more than 190 health systems. The company is also positioning clinical reliability as a competitive focus, launching DoseCheck and a partnership with Wolters Kluwer's UpToDate.
Reductions in hepatitis B surface antigen (HBsAg) were observed with a novel small interfering RNA (siRNA) therapy in patients with chronic hepatitis B virus (HBV) infection, according to a phase II study. Among patients randomized...
Mayo Clinic Platform launched an AI-driven clinical decision support tool. Beginning in November, eligible clinicians will get a specialty-specific chat covering more than 35 specialties plus 22 clinical calculators available via chat or voice dictation.
Results from the TroFuse-005 trial presented at the annual European Society for Medical Oncology congress showed that the investigational antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) significantly improved...
Brepocitinib produced dramatic improvement in patients with cutaneous sarcoidosis, a condition lacking any very effective therapy, in a small phase II trial presented in Orlando. The dual-acting TYK2/JAK1 inhibitor, marketed as Lisraya, was tested in a trial the excerpt describes only as small, without giving a patient count or effect size.
Federal Medicare regulators have finalized rules codifying the drug price negotiation framework created by the Inflation Reduction Act. The action locks in that framework while drugmakers continue to press repeated legal challenges in court.
A practical framework for assessing AI governance, evidence, transparency and post-deployment performance in clinical workflows.
A sham-controlled trial showed that sleeping while using high‑efficiency particulate air (HEPA) filters in the bedroom improved blood sugar control, as highlighted by NYU Langone Health. A smartwatch artificial intelligence...
Regulators approved asundexian, marketed as Sunharbo, as the first factor XIa inhibitor for secondary stroke prevention. The FDA announced the decision on Monday; the drug is an oral, direct, small-molecule inhibitor of FXIa. The excerpt does not state how this changes care for patients.